目的：分析玻璃体切割术(PPV)前玻璃体腔注射康柏西普对增殖期糖尿病视网膜病变(PDR)患者术中并发症和术后视力恢复的影响。

方法：PDR患者94例(均为单眼发病)随机分为试验组(n=47)和对照组(n=47)。均行PPV治疗，试验组PPV前5～7d给予康柏西普玻璃体腔注射，对照组不予此项干预。观察和统计两组患者手术时间、手术操作、并发症及视力恢复效果。

结果：试验组PPV操作时间(72.33±15.71min)显著短于对照组(91.06±19.29min)(P<0.05)。试验组术中电凝止血、医源性裂孔、新生血管出血发生率分别为4%、2%、6%，均明显低于对照组的19%、15%、26%(P<0.05)。在术后3、6mo，两组BCVA、黄斑厚度逐渐显著降低(均P<0.05)，且试验组改善效果均优于对照组(P<0.05)。

结论：PPV术前玻璃体腔注射康柏西普对降低PDR患者术中并发症发生率和促进术后视力恢复有积极影响。

METHODS: Totally 94 patients with PDR(monocular onset)were randomly divided into the experimental group(n=47)and the control group(n=47). All patients were treated by PPV. The experimental group was treated with intravitreal injection of conbercept at 5-7d before PPV while the control group was not given the intervention. The surgical time, surgical procedures, complications and visual recovery in the two groups were observed and statistically analyzed.

RESULTS: The operating time of PPV for the experimental group was significantly shorter than that for the control group(72.33±15.71min vs 91.06±19.29min, P<0.05). The incidence rates of intraoperative electric coagulation hemostasis, iatrogenic breaks and hemorrhage of new vessels in the experimental group(4%, 2% and 6%)were significantly lower than those in the control group(19%, 15% and 26%; P<0.05). The mean Log Mar acuity BCVA and the macular thickness decreased significantly of the two groups at 3mo and 6mo after surgery(P<0.05). The improvement effect in the experimental group was better than that in the control group(P<0.05).

CONCLUSION: The intravitreal injection of conbercept before PPV has a positive effect on reducing the incidence of intraoperative complications and promoting postoperative visual recovery in patients with PDR.